EurekaMag.com logo
+ Translate

Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man


, : Evidence of parasympathetic activity of the angiotensin converting enzyme inhibitor, captopril, in normotensive man. Clinical Science 68(1): 49-56

Captopril (50 mg orally) produced a significant fall in systolic and diastolic blood pressure in 6 normotensive Na replete subjects, without a rise in heart rate. On captopril, there was no change in the expected normal increase in heart rate on standing. Supine plasma noradrenaline [norepinephrine] was not reduced by captopril and normal postural increases were maintained. Atropine (0.04 mg/kg i.v.) reduced the difference in blood pressure change between captopril and placebo. Facial immersion in water produced a bradycardia. This change was abolished by atropine and attenuated both by captopril and edrophonium (10 mg i.v.), a cholinesterase inhibitor. Lying down after 6 min standing produced an immediate transient tachycardia, which was abolished by atropine and attenuated by captopril. Blood pressure and heart rate rose after a cold pressor test on both captopril and placebo. The tachycardia during the Valsalva maneuvre was inhibited by edrophonium and to a lesser extent by captopril. The effects of captopril and edrophonium were additive. Parasympathetic activity of captopril may contribute to its hemodynamic profile.

(PDF same-day service: $19.90)

Accession: 005411630

PMID: 3880523

DOI: 10.1042/cs0680049

Submit PDF Full Text: Here


Submit PDF Full Text

No spam - Every submission is manually reviewed

Due to poor quality, we do not accept files from Researchgate

Submitted PDF Full Texts will always be free for everyone
(We only charge for PDFs that we need to acquire)

Select a PDF file:
Close
Close

Related references

Shepherd, A.N.; Campbell, B.C.; Reid, J.L., 1982: Effects of captopril, an angiotensin-converting enzyme inhibitor, in normotensive sodium-replete volunteers. Captopril (SQ 14 225) was administered to normotensive, sodium-replete volunteers in order to investigate the relationships between its haemodynamic effects and effects on sympathetic activity, the renin-angiotensin-aldosterone system, and plasma-...

Ohmiya Y.; Fujisawa S.; Nakai K., 1984: Effects of angiotensin converting enzyme inhibitors captopril and cv 3317 n n 1 s ethoxycarbonyl 3 phenylpropyl l alanyl n indan 2 yl glycine hydrochloride on angiotensin converting enzyme activities in normotensive rats. Japanese Journal of Pharmacology 36(SUPPL): 303P

Levens, N.R.; Peach, M.J.; Vaughan, E.D.; Weed, W.C.; Carey, R.M., 1981: Responses of blood pressure and angiotensin-converting enzyme activity to acute captopril administration in normotensive and hypertensive rats. The purpose of these experiments ws to determine the dose of captopril which resulted in essentially complete blockade of tissue and plasma converting enzyme activity (CEA) and to correlate the effect of this dose of inhibitor on blood pressure an...

Battistini, B.; Ayach, B.; Molez, Séphanie.; Blouin, A.; Jeng, A.Y., 2002: Effects of benazepril, an angiotensin-converting enzyme inhibitor, combined with CGS 35066, a selective endothelin-converting enzyme inhibitor, on arterial blood pressure in normotensive and spontaneously hypertensive rats. Continuous intra-arterial administration of a selective endothelin-converting enzyme (ECE) inhibitor CGS 35066 at a dose of 30 mg/kg decreased the mean arterial blood pressure (MABP) in conscious unrestrained normotensive rats and spontaneously hy...

Jalil, J.E.; Piddo, A.M.ria; Cordova, S.; Chamorro, G.; Braun, S.; Jalil, R.; Vega, J.; Jadue'p, L.; Lavandero, S.; Lastra, P., 1999: Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. The aim of this study was to estimate the prevalence of the different alleles of the angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and associated plasma ACE activity, as well as cardiac echocardiographic structure,...

Jalil, J.E.; Piddo, A.M.; Cordova, S.; Chamorro, G.; Braun, S.; Jalil, R.; Vega, J.; Jadue'P.L.; Lavandero, S.; Lastra, P., 1999: Prevalence of the angiotensin I converting enzyme insertion/deletion polymorphism, plasma angiotensin converting enzyme activity, and left ventricular mass in a normotensive Chilean population. The aim of this study was to estimate the prevalence of the different alleles of the angiotensin converting enzyme (ACE) gene insertion/deletion (I/D) polymorphism and associated plasma ACE activity, as well as cardiac echocardiographic structure,...

MacGregor, G.A.; Markandu, N.D.; Bayliss, J.; Roulston, J.E.; Squires, M.; Morton, J.J., 1981: Non-sulfhydryl-containing angiotensin-converting enzyme inhibitor (MK421): evidence for role of renin system in normotensive subjects. A non-sulfhydryl-containing inhibitor of angiotensin-converting enzyme (MK421) was given as a single dose in a randomised double-blind cross-over trial using 20 mg and 5 mg of MK-421 or matched placebo to nine normotensive volunteers receiving a s...

Anonymous, 2012: Murine Recombinant Angiotensin-Converting Enzyme 2 Effect on Angiotensin II-Dependent Hypertension and Distinctive Angiotensin-Converting Enzyme 2 Inhibitor Characteristics on Rodent and Human Angiotensin-Converting Enzyme 2 Renin-Angiotensin-Aldosteron. A newly produced murine recombinant angiotensin (Ang)-converting enzyme 2 (ACE2) was characterized in vivo and in vitro. The effects of available ACE2 inhibitors (MLN-4760 and 2 conformational variants of DX600, linear and cyclic) were also examin...

Lindpaintner K.; Qiu X.S.; Wilhelm M.J.; Manwen J.; Ganten D., 1988: Tissue angiotensin converting enzyme activities and their inhibition by the converting enzyme inhibitor cilazapril differ among normotensive and hypertensive rats. Journal of Hypertension 6(SUPPL 4): S729-S730

Numabe A.; Uehara Y.; Takada S.; Hirawa N.; Yagi S., 1988: The effects of an angiotensin converting enzyme inhibitor captopril on vascular phospholipase c activity in spontaneously hypertensive rats. Japanese Circulation Journal 52(9): 911-912